RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.040
+0.010 (0.97%)
Apr 28, 2026, 4:00 PM EDT - Market closed
RedHill Biopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 5 | 5 | 8 | 29 | 13 | 135 | |
| Market Cap Growth | 47.71% | -34.04% | -72.32% | 124.48% | -90.53% | -55.27% | |
| Enterprise Value | 2 | 3 | 1 | 24 | 118 | 188 | |
| Last Close Price | 1.04 | 1.03 | 6.21 | 36.50 | 140.30 | 2580.00 | |
| PE Ratio | - | - | - | 1.20 | - | - | |
| PS Ratio | 18.59 | 18.34 | 0.99 | 4.40 | 0.21 | 1.58 | |
| PB Ratio | 1.25 | 1.23 | -1.70 | 13.88 | -0.26 | 15.23 | |
| EV/Sales Ratio | 8.45 | 9.07 | 0.15 | 3.68 | 1.92 | 2.19 | |
| Debt / Equity Ratio | 0.25 | 0.25 | -0.08 | 0.57 | -2.53 | 9.89 | |
| Net Debt / Equity Ratio | -0.68 | -0.68 | 0.91 | -2.12 | -2.12 | 5.61 | |
| Net Debt / EBITDA Ratio | 0.39 | 0.39 | 0.35 | 0.20 | -2.96 | -0.79 | |
| Net Debt / FCF Ratio | 0.40 | 0.40 | 0.45 | 0.12 | -3.49 | -0.76 | |
| Asset Turnover | 0.01 | 0.01 | 0.39 | 0.07 | 0.36 | 0.48 | |
| Inventory Turnover | - | - | 0.79 | 0.45 | 2.58 | 4.63 | |
| Quick Ratio | 0.21 | 0.21 | 0.34 | 0.44 | 0.28 | 0.87 | |
| Current Ratio | 0.34 | 0.34 | 0.54 | 0.81 | 0.44 | 1.09 | |
| Return on Equity (ROE) | - | - | - | - | - | -859.70% | |
| Return on Assets (ROA) | -22.79% | -22.79% | -37.28% | -15.71% | -15.75% | -28.06% | |
| Return on Capital Employed (ROCE) | -129.10% | -129.10% | 293.20% | -746.30% | 111.00% | -81.40% | |
| Earnings Yield | -8.07% | -8.18% | -103.97% | 83.26% | -560.09% | -72.30% | |
| FCF Yield | -135.33% | -137.19% | -117.93% | -124.74% | -229.63% | -48.20% | |
| Buyback Yield / Dilution | - | - | -375.56% | -320.45% | -32.46% | -27.72% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.